Lataa...
The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common type of liver cancer worldwide. Regorafenib is a multi-kinase inhibitor and the second-line treatment for HCC. Since the PI3K/Akt/mTOR signaling pathway is dysregulated in HCC, we evaluated the therapeutic effects of regorafenib combined with a dual...
Tallennettuna:
| Julkaisussa: | Molecules |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7287658/ https://ncbi.nlm.nih.gov/pubmed/32466169 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/molecules25102454 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|